As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
The one-year data shows that 80% of people benefited from the device. It's implanted in the ankle and stimulates a nerve.
WVU Medicine Reynolds Memorial Hospital recently completed its first implant of the Altaviva device, developed by Medtronic, a new treatment option to ...
Medtronic has been hiking its dividend for nearly 50 consecutive years. It's spinning off its diabetes division to focus on faster-growing businesses. Its strategy makes sense -- and its valuation is ...
The Altaviva tibial neuromodulation system. [Image courtesy of Medtronic] Medtronic (NYSE: MDT) + has shared 12-month data from a pivotal clinical trial evaluating its Altaviva device. Altaviva, an ...
Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, the company's growth drivers and much more. Got a confidential news tip? We want to hear from you ...
Neuroscience Portfolio revenue of $2.558 billion, an increase of 4.1% reported and 2.5% organic, with a mid-single digit increase in Neuromodulation, a mid-single digit increase in Cranial & Spinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results